AU764743C - Glycosaminoglycans having an average molecular weight of 2400 d suitable for the treatment of senile dementia - Google Patents

Glycosaminoglycans having an average molecular weight of 2400 d suitable for the treatment of senile dementia

Info

Publication number
AU764743C
AU764743C AU44052/00A AU4405200A AU764743C AU 764743 C AU764743 C AU 764743C AU 44052/00 A AU44052/00 A AU 44052/00A AU 4405200 A AU4405200 A AU 4405200A AU 764743 C AU764743 C AU 764743C
Authority
AU
Australia
Prior art keywords
molecular weight
glycosaminoglycan
treatment
average molecular
senile dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU44052/00A
Other languages
English (en)
Other versions
AU764743B2 (en
AU4405200A (en
Inventor
Umberto Cornelli
Luigi De Ambrosi
Jawed Fareed
Israel Hanin
John Lee
Stanley Lorens
Ronald F. Mervis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU4405200A publication Critical patent/AU4405200A/en
Application granted granted Critical
Publication of AU764743B2 publication Critical patent/AU764743B2/en
Publication of AU764743C publication Critical patent/AU764743C/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
AU44052/00A 1999-05-14 2000-05-12 Glycosaminoglycans having an average molecular weight of 2400 d suitable for the treatment of senile dementia Ceased AU764743C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI99A001066 1999-05-14
IT1999MI001066A IT1312107B1 (it) 1999-05-14 1999-05-14 Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile
PCT/EP2000/004311 WO2000069444A1 (en) 1999-05-14 2000-05-12 Glycosaminoglycans having an average molecular weight equal to 2400 d suitable for the treatment of senile dementia

Publications (3)

Publication Number Publication Date
AU4405200A AU4405200A (en) 2000-12-05
AU764743B2 AU764743B2 (en) 2003-08-28
AU764743C true AU764743C (en) 2004-03-18

Family

ID=11382970

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44052/00A Ceased AU764743C (en) 1999-05-14 2000-05-12 Glycosaminoglycans having an average molecular weight of 2400 d suitable for the treatment of senile dementia

Country Status (22)

Country Link
US (1) US6979680B1 (enExample)
EP (1) EP1181024B1 (enExample)
JP (1) JP2002544233A (enExample)
KR (1) KR100711142B1 (enExample)
CN (1) CN1178667C (enExample)
AT (1) ATE288761T1 (enExample)
AU (1) AU764743C (enExample)
CA (1) CA2373975A1 (enExample)
CZ (1) CZ20014092A3 (enExample)
DE (1) DE60018061T2 (enExample)
DK (1) DK1181024T3 (enExample)
ES (1) ES2237425T3 (enExample)
HK (1) HK1039903B (enExample)
HU (1) HUP0201100A3 (enExample)
IL (1) IL146458A0 (enExample)
IT (1) IT1312107B1 (enExample)
NO (1) NO328902B1 (enExample)
PL (1) PL198016B1 (enExample)
PT (1) PT1181024E (enExample)
RU (1) RU2248800C2 (enExample)
WO (1) WO2000069444A1 (enExample)
ZA (1) ZA200109331B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1344781A1 (en) * 2002-03-12 2003-09-17 Laboratori Derivati Organici S.P.A. Process for the depolymerization of glycosaminoglycanes and products obtained therefrom
ITMI20031023A1 (it) * 2003-05-21 2004-11-22 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali.
EP1524276A1 (en) * 2003-10-16 2005-04-20 Laboratori Derivati Organici S.P.A. Multistep process for the physical depolymerization of heparin and products obtained therefrom
US7939512B2 (en) 2004-10-13 2011-05-10 Laboratori Derivati Organici Spa Multistep process for the physical depolymerization of heparin and products obtained therefrom
ATE481094T1 (de) 2005-12-22 2010-10-15 Kiacta Sarl Behandlung von diabetischer nephropathie
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
EP2283709B1 (en) 2008-05-22 2018-07-11 Vladimir Yegorovich Balakin Charged particle cancer therapy patient positioning apparatus
US8901509B2 (en) 2008-05-22 2014-12-02 Vladimir Yegorovich Balakin Multi-axis charged particle cancer therapy method and apparatus
US8896239B2 (en) 2008-05-22 2014-11-25 Vladimir Yegorovich Balakin Charged particle beam injection method and apparatus used in conjunction with a charged particle cancer therapy system
WO2009142546A2 (en) 2008-05-22 2009-11-26 Vladimir Yegorovich Balakin Multi-field charged particle cancer therapy method and apparatus
JP2011523169A (ja) 2008-05-22 2011-08-04 エゴロヴィチ バラキン、ウラジミール 荷電粒子癌治療システムと併用する荷電粒子ビーム抽出方法及び装置
AU2009341615B2 (en) 2009-03-04 2013-03-28 Zakrytoe Aktsionernoe Obshchestvo Protom Multi-field charged particle cancer therapy method and apparatus
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US20140302510A1 (en) 2012-04-06 2014-10-09 Centre National De La Recherche Scientifique Method of diagnosis, prognostic or treatment of neurodegenerative diseases
CN112426434A (zh) * 2020-11-04 2021-03-02 山东大学 硫酸乙酰肝素在防治阿尔兹海默症中的应用
CN114478816A (zh) * 2022-02-11 2022-05-13 上海兴糖生物技术有限公司 一种白玉蜗牛多糖及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0243974A2 (en) * 1986-05-01 1987-11-04 Toppan Printing Co., Ltd. Scanner set-up simulation apparatus
EP0450508A2 (en) * 1990-04-03 1991-10-09 Mediolanum Farmaceutici S.P.A. Use of dermatan sulphate for the prevention and therapy of cerebral aging and of central nervous system functional deficit states

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
IT1213384B (it) * 1986-11-24 1989-12-20 Lab Derivati Organici Mediolan Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare.
IT1205042B (it) 1987-05-28 1989-03-10 Crinos Industria Farmaco Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer
EP0337327A1 (en) * 1988-04-09 1989-10-18 Bioiberica, S.A. Process for the preparation of new oligosaccharide fractions by controlled chemical depolimerization of heparin
IL100555A (en) * 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
SK279285B6 (sk) * 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0243974A2 (en) * 1986-05-01 1987-11-04 Toppan Printing Co., Ltd. Scanner set-up simulation apparatus
EP0450508A2 (en) * 1990-04-03 1991-10-09 Mediolanum Farmaceutici S.P.A. Use of dermatan sulphate for the prevention and therapy of cerebral aging and of central nervous system functional deficit states

Also Published As

Publication number Publication date
PL198016B1 (pl) 2008-05-30
EP1181024B1 (en) 2005-02-09
CZ20014092A3 (cs) 2002-04-17
KR100711142B1 (ko) 2007-04-24
DE60018061T2 (de) 2006-04-13
US6979680B1 (en) 2005-12-27
ATE288761T1 (de) 2005-02-15
HK1039903B (en) 2005-08-26
AU764743B2 (en) 2003-08-28
NO20015544L (no) 2002-01-14
CN1350459A (zh) 2002-05-22
ITMI991066A1 (it) 2000-11-14
HUP0201100A2 (hu) 2002-07-29
DK1181024T3 (da) 2005-06-13
WO2000069444A1 (en) 2000-11-23
PL352070A1 (en) 2003-07-28
IT1312107B1 (it) 2002-04-04
NO328902B1 (no) 2010-06-14
EP1181024A1 (en) 2002-02-27
PT1181024E (pt) 2005-06-30
ZA200109331B (en) 2002-08-28
KR20020005033A (ko) 2002-01-16
NO20015544D0 (no) 2001-11-13
DE60018061D1 (de) 2005-03-17
IL146458A0 (en) 2002-07-25
AU4405200A (en) 2000-12-05
JP2002544233A (ja) 2002-12-24
HUP0201100A3 (en) 2003-03-28
CN1178667C (zh) 2004-12-08
HK1039903A1 (en) 2002-05-17
CA2373975A1 (en) 2000-11-23
ES2237425T3 (es) 2005-08-01
RU2248800C2 (ru) 2005-03-27

Similar Documents

Publication Publication Date Title
EP1181024B1 (en) Use of glycosaminoglycans for the treatment of senile dementia
US4757057A (en) Oligo-heteropolysaccharides having a heparin-like activity method for their preparation and pharmaceutical compositions based thereon
US5250519A (en) Non-anticoagulant heparin derivatives
AU618346B2 (en) Sulfoamino derivatives of chondroitin sulfates, of dermatan sulfate and of hyaluronic acid and their pharmacological properties
JP2018154848A (ja) 低抗凝固剤ヘパリン
JPH04503950A (ja) 平滑筋細胞増殖のインヒビターとしてのヘパリン断片
JPH06507635A (ja) 病理学的過程の予防および／または治療用組成物
EA011417B1 (ru) Олигосахаридальгината и его производные, способ получения и применение
US5605891A (en) Use of polysaccharides in acute peripheral neuropathies
RS56874B1 (sr) Glikozaminoglikani koji nisu antikoagulanti koji sadrže ponavljajuću jedinicu disaharida i njihova medicinska upotreba
US6573251B2 (en) Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
AU2012252415B2 (en) "Biotechnological sulphated chondroitin sulphate at position 4 or 6 on the same polysaccharide chain, and process for the preparation thereof"
Walzer et al. Low molecular weight glycosaminoglycan blockade of β-amyloid induced neuropathology
JPH03243601A (ja) 血液凝固の制御能をもつムコ多糖組成物およびその製造方法
JP4149545B2 (ja) 低分子量のフカン類とその医薬組成物
CA3022455C (en) Cyclodextrins as procoagulants
EP0635519B1 (en) Polyglucuronic acid as remitting agent for nephrotic syndrome and hepatopathy symptoms
JPH10503168A (ja) 神経系の損傷の処置のための置換デキストランの使用ならびにヘパラン硫酸に富む分画
TW200922605A (en) Composition and treatment
Krzywkowski Céline Morissette, Diane Lacombe, Xianqi Kong, Ahmed Aman, Pascale Krzywkowski, Lioudmila Rodionova, Mounia Azzi, Daniel Delorme, and Barry D. Greenberg

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 15, NO 10, PAGE(S) 1850-1853 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 43862/00 AND 44052/00

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20030903

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20031002

FGA Letters patent sealed or granted (standard patent)
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: THE INVENTION TITLE SHOULD READ: GLYCOSAMINOGLYCANS HAVING AN AVERAGE MOLECULAR WEIGHT OF 2400 D SUITABLE FOR THE TREATMENT OF SENILE DEMENTIA